对违反银行保密义务行为之探析

商业银行法第二十九条第一款、第二款,第三十条与第五十三条这三条规定可说是我国有关银行保密方面规定得最直接的规定,但规定得很笼统,对违反银行保密义务的行为,是侵权还是违约,要负何种民事责任,应该怎样承担的问题,商业银行法并没有作出具体规定,仅有在第七十三条第四款对银行应该承担民事责任的笼统规定,可以说是立法的一大缺陷,因此本文将对此进行论述

Synthesis and Solution Properties of Polyacrylamide Containing Sulfobetaine Groups

用丙烯酰胺(AM)、n,n-二甲基丙烯酰胺(dMAM)、[3-(甲基乙烯酰胺)丙基]二甲基-(3-磺酸)铵(dMMPPS)和[2-(甲基丙烯酰基氧基)乙基]二甲基-(3-磺酸丙基)氢氧化铵(dMAPS)单体通过氧化还原引发剂引发自由基聚合合成AM-dMMPPS、AM-dMAM-dMMPPS、AM-dMAPS和AM-dMAM-dMAPS 4种两性离子共聚物,并对两性离子聚合物进行表征和性能评价.研究结果表明,实验合成的4种共聚物AM-dMMPPS、AM-dMAMdMMPPS、AM-dMAPS和AM-dMAM-dMAPS都有增黏、抗盐、耐温的效果.在相同的反应条件下,在合成的共聚物中,AM-dMMPPS增黏、抗盐、耐温的效果最佳,其比浓黏度达36.8,dl/g.Four kinds of zwitterionic copolymers(AM-DMMPPS,AM-DMAM-DMMPPS,AM-DMAPS and AMDMAM-DMAPS) were synthesized by free radical copolymerization of acrylamide(AM), N, Ndimethylacrylamide(DMAM),[3-(methacryloylamino)propyl]dimethyl(3-sulfopropyl) ammonium hydroxide inner salt(DMMPPS)and [2-(Methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide(DMAPS).The copolymers were characterized and their solution properties were evaluated.The results show that the existence of the copolymers enhances the viscosity of the aqueous solution and the copolymers exhibit favorable salt resistant and thermal stable properties.At the same condition of copolymerization,in all synthesized copolymers,the AMDMMPPS copolymer has the most excellent properties of aqueous thickening and heat and salt resistant effect,and the highest reduced viscosity of the copolymer solution is 36.8,dL/g.国家自然科学基金资助项目(20876108

The Lycodon gongshan Found in Panzhihua City of Sichuan Province, China

2014年9月至2017年9月,在四川省境内的攀枝花大黑山森林公园、攀枝花盐边县红宝苗族彝族乡共采集到贡山链蛇(Lycodon gongshan Vogel and Luo,2011)标本2号,为四川省首次发现该物种。2号标本(标本号R20140901和PZH20170901)保存在中国科学院成都生物研究所

重离子束流横向剂量分布测量探测器及其二维成像方法

本发明涉及重离子束(包括质子束)治疗肿瘤技术的领域，尤其涉及到重离子束流横向剂量分布测量探测器及其二维成像方法，其主要特点是包括气体密封腔(1)，其内设有电离室内芯(2)，与电离室内芯(2)电连接的多路信号转接板(3)；所述的气体密封腔(1)由主体框架(1-1)和入射窗(1-2)、出射窗(1-3)组成；所述的电离室内芯(2)由两组电离室单元组成，每个单元电离室均由信号极(2-1)、绝缘垫板(2-2)和高压极(2-3)组成；所述的多路信号转接板(3)的一端设有接触端(3-3)插入气体密封腔(1)的密封口(1-5)与电离室内芯(2)的信号极(2-1)相连，另一端设有多芯连接器(3-2)为束流剖面监测探测器的信号输出端口

Aripiprazole versus other atypical antipsychotics for schizophrenia

BACKGROUND: In most western industrialised countries, second generation (atypical) antipsychotics are recommended as first line drug treatments for people with schizophrenia. In this review we specifically examine how the efficacy and tolerability of one such agent - aripiprazole - differs from that of other comparable second generation antipsychotics. OBJECTIVES: To evaluate the effects of aripiprazole compared with other atypical antipsychotics for people with schizophrenia and schizophrenia-like psychoses. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (November 2011), inspected references of all identified studies for further trials, and contacted relevant pharmaceutical companies, drug approval agencies and authors of trials for additional information. SELECTION CRITERIA: We included all randomised clinical trials (RCTs) comparing aripiprazole (oral) with oral and parenteral forms of amisulpride, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone or zotepine for people with schizophrenia or schizophrenia-like psychoses. DATA COLLECTION AND ANALYSIS: We extracted data independently. For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CI) on an intention-to-treat basis based on a random-effects model. Where possible, we calculated illustrative comparative risks for primary outcomes. For continuous data, we calculated mean differences (MD), again based on a random-effects model. We assessed risk of bias for each included study. MAIN RESULTS: We included 12 trials involving 6389 patients. Aripiprazole was compared to olanzapine, risperidone and ziprasidone. All trials were sponsored by an interested drug manufacturer. The overall number of participants leaving studies early was 30% to 40%, limiting validity (no differences between groups).When compared with olanzapine no differences were apparent for global state (no clinically important change: n = 703, 1 RCT, RR short-term 1.00 95% CI 0.81 to 1.22; n = 317, 1 RCT, RR medium-term 1.08 95% CI 0.95 to 1.22) but mental state tended to favour olanzapine (n = 1360, 3 RCTs, MD total Positive and Negative Syndrome Scale (PANSS) 4.68 95% CI 2.21 to 7.16). There was no significant difference in extrapyramidal symptoms (n = 529, 2 RCTs, RR 0.99 95% CI 0.62 to 1.59) but fewer in the aripiprazole group had increased cholesterol levels (n = 223, 1 RCT, RR 0.32 95% CI 0.19 to 0.54) or weight gain of 7% or more of total body weight (n = 1095, 3 RCTs, RR 0.39 95% CI 0.28 to 0.54).When compared with risperidone, aripiprazole showed no advantage in terms of global state (n = 384, 2 RCTs, RR no important improvement 1.14 95% CI 0.81 to 1.60) or mental state (n = 372, 2 RCTs, MD total PANSS 1.50 95% CI -2.96 to 5.96).One study compared aripiprazole with ziprasidone (n = 247) and both the groups reported similar change in the global state (n = 247, 1 RCT, MD average change in Clinical Global Impression-Severity (CGI-S) score -0.03 95% CI -0.28 to 0.22) and mental state (n = 247, 1 RCT, MD change PANSS -3.00 95% CI -7.29 to 1.29).When compared with any one of several new generation antipsychotic drugs the aripiprazole group showed improvement in global state in energy (n = 523, 1 RCT, RR 0.69 95% CI 0.56 to 0.84), mood (n = 523, 1 RCT, RR 0.77 95% CI 0.65 to 0.92), negative symptoms (n = 523, 1 RCT, RR 0.82 95% CI 0.68 to 0.99), somnolence (n = 523, 1 RCT, RR 0.80 95% CI 0.69 to 0.93) and weight gain (n = 523, 1 RCT, RR 0.84 95% CI 0.76 to 0.94). Significantly more people given aripiprazole reported symptoms of nausea (n = 2881, 3 RCTs, RR 3.13 95% CI 2.12 to 4.61) but weight gain (7% or more of total body weight) was less common in people allocated aripiprazole (n = 330, 1 RCT, RR 0.35 95% CI 0.19 to 0.64). Aripiprazole may have value in aggression but data are limited. This will be the focus of another review. AUTHORS' CONCLUSIONS: Information on all comparisons are of limited quality, are incomplete and problematic to apply clinically. Aripiprazole is an antipsychotic drug with a variant but not absent adverse effect profile. Long-term data are sparse and there is considerable scope for another update of this review as new data emerges from the many Chinese studies as well as from ongoing larger, independent pragmatic trials

JUNO Sensitivity on Proton Decay p→νˉK+p\to \bar\nu K^+ Searches

The Jiangmen Underground Neutrino Observatory (JUNO) is a large liquid scintillator detector designed to explore many topics in fundamental physics. In this paper, the potential on searching for proton decay in $p\to \bar\nu K^+$ mode with JUNO is investigated.The kaon and its decay particles feature a clear three-fold coincidence signature that results in a high efficiency for identification. Moreover, the excellent energy resolution of JUNO permits to suppress the sizable background caused by other delayed signals. Based on these advantages, the detection efficiency for the proton decay via $p\to \bar\nu K^+$ is 36.9% with a background level of 0.2 events after 10 years of data taking. The estimated sensitivity based on 200 kton-years exposure is $9.6 \times 10^{33}$ years, competitive with the current best limits on the proton lifetime in this channel

JUNO sensitivity on proton decay p → ν K + searches*

The Jiangmen Underground Neutrino Observatory (JUNO) is a large liquid scintillator detector designed to explore many topics in fundamental physics. In this study, the potential of searching for proton decay in the $p\to \bar{\nu} K^+$ mode with JUNO is investigated. The kaon and its decay particles feature a clear three-fold coincidence signature that results in a high efficiency for identification. Moreover, the excellent energy resolution of JUNO permits suppression of the sizable background caused by other delayed signals. Based on these advantages, the detection efficiency for the proton decay via $p\to \bar{\nu} K^+$ is 36.9% ± 4.9% with a background level of $0.2\pm 0.05({\rm syst})\pm$$0.2({\rm stat})$ events after 10 years of data collection. The estimated sensitivity based on 200 kton-years of exposure is $9.6 \times 10^{33}$ years, which is competitive with the current best limits on the proton lifetime in this channel and complements the use of different detection technologies